| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | -207.6MM | -283% |
| Operating Income | 37.6MM | -6% |
| Operating Expenses | - | - |
| Net Income | 1B | - |
| R&D | 35.7MM | +8% |
| G&A | 38.7MM | +7% |
| Interest Expense | 8.4MM | -14% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
Healthcare stocks, especially biotech companies, are very risky for investors. Their share price can be highly volatile and surge higher or plummet lower based on news regarding a clinical trial, treatment authorization, or any number of events that could be or break a company. In other industries, this massive shift in price action isn’t nearly as prevalent. Some biotech companies are failing and won’t offer investors much in the way of returns. And they should be ditched from any watchlist bec
Shares of Ironwood Pharmaceuticals collapsed Thursday on mixed results for its gastrointestinal drug. The biotech stock erased a 38% gain.
BOSTON, February 29, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced positive topline results from its pivotal Phase III STARS trial, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). SBS-IF, a rare and severe organ failure condition in which patients are dependent on PS, affects an estimat
BOSTON, February 23, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference. ASPEN is being held from March 2-5, 2024, in
Ironwood Pharmaceuticals ( NASDAQ:IRWD ) Full Year 2023 Results Key Financial Results Revenue: US$442.7m (up 7.8% from...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2023 Earnings Call Transcript February 15, 2024 Ironwood Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.01 EPS, expectations were $0.2. IRWD isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome […]
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
Q4 2023 Ironwood Pharmaceuticals Inc Earnings Call
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 0.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?